Wall Street brokerages expect that Aetna (NYSE:AET) will post sales of $15.51 billion for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Aetna’s earnings, with estimates ranging from $15.18 billion to $15.92 billion. Aetna posted sales of $15.50 billion in the same quarter last year, which would indicate a positive year over year growth rate of 0.1%. The company is expected to announce its next earnings results on Thursday, August 2nd.
On average, analysts expect that Aetna will report full-year sales of $61.41 billion for the current financial year, with estimates ranging from $59.49 billion to $63.44 billion. For the next year, analysts anticipate that the company will report sales of $64.83 billion per share, with estimates ranging from $61.51 billion to $67.69 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Aetna.
Aetna (NYSE:AET) last released its quarterly earnings data on Tuesday, May 1st. The company reported $3.19 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.97 by $0.22. The business had revenue of $15.34 billion during the quarter, compared to analysts’ expectations of $15.32 billion. Aetna had a net margin of 5.76% and a return on equity of 21.42%. The firm’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same period in the prior year, the company earned $2.71 EPS.
A number of equities analysts recently issued reports on AET shares. Jefferies Group reiterated a “hold” rating and set a $205.00 price objective on shares of Aetna in a research report on Wednesday, January 31st. Deutsche Bank upgraded shares of Aetna from a “hold” rating to a “buy” rating and upped their price objective for the stock from $195.00 to $212.00 in a research report on Monday, January 22nd. Citigroup cut shares of Aetna from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $187.89 to $212.00 in a research report on Wednesday, January 31st. Cowen reiterated a “buy” rating and set a $212.00 price objective on shares of Aetna in a research report on Tuesday, January 30th. Finally, Credit Suisse Group upped their price objective on shares of Aetna from $200.00 to $208.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 31st. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Aetna currently has a consensus rating of “Buy” and an average target price of $196.36.
A number of hedge funds and other institutional investors have recently made changes to their positions in AET. Farallon Capital Management LLC acquired a new position in Aetna in the 4th quarter valued at approximately $940,734,000. Summit Trail Advisors LLC boosted its stake in shares of Aetna by 55,803.4% in the 1st quarter. Summit Trail Advisors LLC now owns 1,616,727 shares of the company’s stock valued at $1,617,000 after purchasing an additional 1,613,835 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Aetna by 101.0% in the 1st quarter. Wells Fargo & Company MN now owns 2,797,748 shares of the company’s stock valued at $472,819,000 after purchasing an additional 1,405,859 shares during the last quarter. Abrams Capital Management L.P. bought a new stake in shares of Aetna in the 1st quarter valued at $233,220,000. Finally, Deutsche Bank AG boosted its stake in shares of Aetna by 57.5% in the 4th quarter. Deutsche Bank AG now owns 2,704,723 shares of the company’s stock valued at $487,900,000 after purchasing an additional 987,156 shares during the last quarter. Hedge funds and other institutional investors own 84.19% of the company’s stock.
Aetna traded down $0.51, reaching $177.21, during trading on Thursday, Marketbeat.com reports. 2,348,000 shares of the company were exchanged, compared to its average volume of 2,394,661. The stock has a market cap of $57.83 billion, a price-to-earnings ratio of 17.97, a P/E/G ratio of 1.49 and a beta of 0.64. Aetna has a twelve month low of $140.57 and a twelve month high of $194.40. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.73 and a quick ratio of 0.73.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 1st. Shareholders of record on Wednesday, July 25th will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.13%. The ex-dividend date is Tuesday, July 24th. Aetna’s dividend payout ratio (DPR) is currently 20.28%.
Aetna Inc operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aetna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna and related companies with MarketBeat.com's FREE daily email newsletter.